Total (n = 60) | Low UPCR (n = 36) | High UPCR (n = 24) | P* | |
---|---|---|---|---|
Mean age, years (range) | 67.4 (36–86) | 67.2 (36–86) | 67.8 (46–82) | 0.958 |
Male, n(%) | 38 (63.3) | 22 (61.1) | 16 (66.7) | 0.66 |
Mean body weight, Kg (range) | 57.5 (32.7–101) | 54.5 (32.7–81.5) | 62.0 (44.4–101) | 0.036 |
ECOG PS, n(%) | 0.831 | |||
0 | 43 (72) | 25 (69) | 18 (75) | |
1 | 11 (18) | 7 (19) | 4 (17) | |
2 | 2 (3) | 2 (6) | 0 | |
unknown | 4 (7) | 2 (6) | 2 (8) | |
Primary Site | 0.50 | |||
Gastric cancer | 11 (18) | 8 (22) | 3 (13) | |
Colorectal cancer | 49 (82) | 28 (78) | 21 (88) | |
Pathological status | 1 | |||
tub1/tub2 | 47 (78) | 28 (78) | 19 (79) | |
others | 13 (22) | 8 (22) | 5 (21) | |
Used anti-VEGF/Ri | 1 | |||
Bevacizumab | 41 (68) | 25 (69) | 16 (67) | |
Ramucirumab | 17 (28) | 10 (28) | 7 (29) | |
Aflibercept | 2 (3) | 1 (3) | 1 (4) | |
RAS inhibitor usage | 0.06 | |||
YES | 17 (28) | 7 (19) | 10 (42) | |
NO | 43 (72) | 29 (81) | 14 (58) | |
Prior anti-VEGF/Ri usage | 0.65 | |||
YES | 18 (30) | 10 (28) | 8 (33) | |
NO | 42 (70) | 26 (72) | 16 (67) | |
Onset QV status (%) | 0.013 | |||
2+ | 53 (88) | 35 (97) | 18 (75) | |
3+ or more | 7 (12) | 1 (3) | 6 (25) | |
Worst QV status | < 0.001 | |||
2+ | 34 (57) | 30 (83) | 4 (17) | |
3+ or more | 26 (43) | 6 (17) | 20 (83) |